Sudarshan Pharma Industries Ltd is Rated Buy

Understanding the Current Rating

The Buy rating assigned to Sudarshan Pharma Industries Ltd indicates a positive outlook based on a comprehensive evaluation of the company’s quality, valuation, financial trend, and technical indicators. This rating suggests that the stock is expected to deliver favourable returns relative to its peers and the broader market, making it an attractive option for investors seeking growth within the specialty chemicals sector.

Quality Assessment

As of 01 June 2026, Sudarshan Pharma’s quality grade is assessed as average. This reflects a stable operational foundation with consistent profitability and growth metrics. The company has demonstrated healthy long-term growth, with operating profit expanding at an annualised rate of 47.89%. Such growth underscores the firm’s ability to scale its operations effectively while maintaining profitability. Additionally, recent quarterly results for March 2026 show a significant improvement, with profit before tax excluding other income (PBT LESS OI) reaching ₹11.57 crores, marking a 120.9% increase compared to the previous four-quarter average. This surge highlights operational efficiency and robust demand for the company’s products.

Valuation Perspective

Valuation remains a key factor in the Buy rating, with Sudarshan Pharma currently graded as attractive in this regard. The company’s return on capital employed (ROCE) stands at 10.5%, which, combined with an enterprise value to capital employed ratio of 2.6, indicates that the stock is reasonably priced relative to the capital it utilises to generate earnings. The price-to-earnings growth (PEG) ratio of 1.1 further supports this view, suggesting that the stock’s price is aligned with its earnings growth potential. Investors looking for value within the specialty chemicals sector may find this valuation compelling, especially given the company’s growth trajectory.

Financial Trend and Performance

The financial trend for Sudarshan Pharma is positive, reflecting both strong recent results and sustained growth over time. The latest quarterly figures reveal the highest net sales recorded at ₹220.92 crores and the highest profit before depreciation, interest, and taxes (PBDIT) at ₹20.19 crores. These milestones indicate expanding market share and operational leverage. Over the past year, the stock has delivered an 18.03% return, while profits have increased by 36%, demonstrating a healthy correlation between earnings growth and shareholder returns. Year-to-date, the stock has appreciated by 25.95%, outperforming many peers in the specialty chemicals sector. This consistent upward trend reinforces the positive financial momentum underpinning the Buy rating.

Technical Analysis

From a technical standpoint, Sudarshan Pharma is graded as bullish. The stock’s price movements over various time frames support this view, with a 1-month gain of 14.67%, a 3-month increase of 23.66%, and a 6-month rise of 31.54%. These gains reflect strong investor interest and positive market sentiment. The stock’s ability to outperform the BSE500 index over the last three years, one year, and three months further validates its technical strength. For investors who incorporate technical analysis into their decision-making, these indicators suggest favourable entry points and sustained upward momentum.

Market Capitalisation and Sector Context

Sudarshan Pharma Industries Ltd is classified as a microcap company within the specialty chemicals sector. While microcap stocks can carry higher volatility, the company’s solid fundamentals and positive technical signals provide a degree of confidence for investors willing to engage with smaller-capitalisation firms. The specialty chemicals sector itself is known for its cyclical nature and growth potential, driven by industrial demand and innovation. Sudarshan Pharma’s performance within this sector highlights its competitive positioning and growth prospects.

Summary for Investors

In summary, the Buy rating for Sudarshan Pharma Industries Ltd reflects a balanced assessment of its current strengths and growth potential. Investors should note that this rating was last updated on 20 May 2026, but the financial and market data presented here are current as of 01 June 2026, ensuring an accurate and timely perspective. The company’s average quality grade, attractive valuation, positive financial trend, and bullish technical indicators collectively support the recommendation to consider this stock for portfolio inclusion. While microcap stocks entail certain risks, Sudarshan Pharma’s demonstrated growth and market-beating returns make it a noteworthy candidate for investors seeking exposure to the specialty chemicals sector.

Long-Term Growth and Market Performance

Examining Sudarshan Pharma’s long-term performance reveals a compelling growth story. The company’s operating profit has expanded at an impressive annual rate of 47.89%, signalling robust operational execution and market demand. Over the past three years, the stock has consistently outperformed the BSE500 index, underscoring its ability to generate superior returns relative to the broader market. This outperformance is not limited to long-term horizons; the stock’s recent 3-month and 6-month returns of 23.66% and 31.54%, respectively, demonstrate sustained momentum. Such performance metrics are critical for investors seeking stocks with both growth and resilience.

Recent Quarterly Highlights

The March 2026 quarter was particularly noteworthy for Sudarshan Pharma. The company achieved its highest quarterly net sales of ₹220.92 crores, reflecting strong demand and effective sales strategies. Profit before depreciation, interest, and taxes (PBDIT) also reached a record ₹20.19 crores, indicating improved operational efficiency. The profit before tax excluding other income (PBT LESS OI) surged by 120.9% compared to the previous four-quarter average, highlighting a significant earnings acceleration. These results provide a solid foundation for the company’s positive outlook and justify the current Buy rating.

Valuation Metrics in Detail

Investors often seek stocks that combine growth with reasonable valuation, and Sudarshan Pharma fits this criterion well. The company’s ROCE of 10.5% suggests effective utilisation of capital to generate profits. The enterprise value to capital employed ratio of 2.6 indicates that the stock is not overvalued relative to its capital base. Furthermore, the PEG ratio of 1.1 implies that the stock’s price is in line with its earnings growth, making it an attractive proposition for growth-oriented investors. These valuation metrics support the view that Sudarshan Pharma offers a favourable risk-reward profile.

Technical Strength and Market Sentiment

The bullish technical grade assigned to Sudarshan Pharma reflects strong market sentiment and positive price momentum. The stock’s recent price performance, including a 1-month gain of 14.67% and a 6-month increase of 31.54%, indicates sustained buying interest. This momentum is further supported by the stock’s ability to outperform benchmark indices over multiple time frames. For investors who incorporate technical analysis into their investment process, these signals suggest that the stock is well-positioned for continued appreciation in the near term.

Conclusion

Overall, Sudarshan Pharma Industries Ltd’s Buy rating by MarketsMOJO is grounded in a thorough analysis of its current fundamentals, valuation, financial trends, and technical outlook. The rating update on 20 May 2026 reflects the company’s evolving prospects, while the data as of 01 June 2026 confirms its strong market position and growth trajectory. Investors considering exposure to the specialty chemicals sector should weigh these factors carefully, recognising the stock’s potential for attractive returns balanced against the inherent risks of microcap investing.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →